BlackRock
XLO icon

BlackRock’s Xilio Therapeutics XLO Stock Holding History

BlackRock’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$83.9K Buy
+8,757
New +$73.1K ﹤0.01% 5043
2026
Q1 		– Sell
-146
Closed -$1.3K – 5805
2025
Q4 		$1.3K Hold
146
– – ﹤0.01% 5415
2025
Q3 		$1.72K Hold
146
– – ﹤0.01% 5325
2025
Q2 		$1.39K Sell
146
-5,190
-97% -$54.8K ﹤0.01% 5339
2025
Q1 		$54.1K Sell
5,336
-99
-2% -$1.24K ﹤0.01% 4906
2024
Q4 		$72.7K Buy
5,435
+33
+0.6% +$454 ﹤0.01% 4855
2024
Q3 		$59.6K Buy
5,402
+658
+14% +$8.08K ﹤0.01% 4774
2024
Q2 		$62.9K Buy
4,744
+1,504
+46% +$23.5K ﹤0.01% 4811
2024
Q1 		$49K Sell
3,240
-107
-3% -$1.03K ﹤0.01% 4873
2023
Q4 		$25.8K Sell
3,347
-38
-1% -$751 ﹤0.01% 5054
2023
Q3 		$100K Sell
3,385
-130
-4% -$4.85K ﹤0.01% 4851
2023
Q2 		$129K Sell
3,515
-128
-4% -$5.45K ﹤0.01% 4843
2023
Q1 		$162K Buy
3,643
+112
+3% +$4.92K ﹤0.01% 4832
2022
Q4 		$133K Buy
3,531
+220
+7% +$7.42K ﹤0.01% 4958
2022
Q3 		$135K Sell
3,311
-94
-3% -$3.65K ﹤0.01% 5084
2022
Q2 		$139K Sell
3,405
-18,006
-84% -$952K ﹤0.01% 5140
2022
Q1 		$2.12M Sell
21,411
-1,739
-8% -$275K ﹤0.01% 4364
2021
Q4 		$5.18M Buy
+23,150
New +$5.52M ﹤0.01% 3984

Other funds holding XLO

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KFI
Key Financial Inc West Chester, Pennsylvania $611M AUM 21.11% 1-Year Est. Return

BlackRock's XLO Position: Q2 2026 in Review

BlackRock opened a new position in Xilio Therapeutics (XLO) in Q2 2026: 8,757 shares worth $83.9K. The stake represents ﹤0.01% of the portfolio and ranks #5043 among its holdings. This is a return to the name: BlackRock previously reported a position in XLO as recently as Q4 2025.

BlackRock first reported a position in XLO in Q4 2021 and has held it in 18 quarters since. The position peaked at $5.18M in Q4 2021. 6 funds tracked by Wall St. Rank hold XLO as of Q2 2026.

  • BlackRock held 8,757 shares of Xilio Therapeutics worth $83.9K as of Q2 2026.
  • Xilio Therapeutics was a new BlackRock position in Q2 2026.
  • Xilio Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #5043 holding.
  • BlackRock first reported a position in Xilio Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • BlackRock's Xilio Therapeutics position peaked at $5.18M in Q4 2021.
  • 6 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.